Health Communication for Policymakers: What Actually Translates

The gap between health research and health policy is not primarily a gap in knowledge. The research base for most major public health interventions — tobacco control, childhood vaccination, lead paint remediation, alcohol taxation — is extensive, robust, and has been so for decades before those interventions became established policy. The gap is a translation problem: researchers communicate in a vocabulary and a format optimized for scientific audiences, and policymakers operate in a vocabulary and format optimized for political decision-making. These are not the same language, and producing one does not automatically produce the other.

The Robert Wood Johnson Foundation's research on health policy communication, conducted over several decades of grantmaking in the field, has identified a consistent finding: the health research that influences policy is not always the best science. It is often the research that has been communicated most clearly in the terms policymakers use to evaluate it — terms of cost, of political feasibility, of constituent impact, and of comparative effectiveness against alternatives the policymakers are already considering. The science that cannot be stated in those terms rarely reaches the level of the decision.

How Congressional Staff and Executive Branch Analysts Use Health Research

Congressional staff responsible for health policy — typically policy directors and legislative assistants on committees with health jurisdiction, such as the Senate Finance Committee, the Senate HELP Committee, or the House Energy and Commerce Committee — are not scientists. They hold political science, law, or public policy degrees and work under intense time pressure on multiple issues simultaneously. Their use of health research is instrumental: they need to know whether a proposed policy is supported by evidence, what the evidence says about likely outcomes and costs, and how to respond to opposing arguments.

The format of health research that serves this audience is the policy brief — not the systematic review, not the meta-analysis, and not the journal article. The policy brief is a 2-4 page document that states the policy problem, summarizes the relevant evidence, identifies the policy options and their evidence-based expected outcomes, and makes a specific recommendation. It is written to be read in full in 10-15 minutes and to equip a non-specialist reader with enough information to advocate for or against a specific policy position.

Executive branch analysts — in the Office of Management and Budget, the White House Domestic Policy Council, or agencies like CDC, CMS, or HRSA — read health research in a similar instrumental mode but with different primary concerns. Budget implications, implementation feasibility, and regulatory consistency are primary. Scientific rigor is assumed rather than interrogated — executive branch analysts rely on agency scientific staff to assess research quality and translate it into policy-relevant terms.

What a Policy Brief Should Accomplish vs. a Systematic Review

A systematic review is the gold standard for synthesizing evidence on a clinical or public health question. Its purpose is to provide a complete, unbiased summary of the available evidence, including its quality, its consistency, and the gaps in the literature. A well-conducted systematic review answers the question: "What does the evidence show, and how certain are we?"

This is not the question a policymaker is asking. The policymaker's question is: "Given what we know, what should we do?" The systematic review answers the former question — the policymaker needs someone to bridge the gap to the latter. The policy brief is that bridge.

The structural difference between the two documents reflects this functional difference. A systematic review devotes the majority of its length to methods, inclusion criteria, risk of bias assessment, and heterogeneity analysis — precisely because its credibility rests on transparent methodology. A policy brief devotes its first page to the policy problem and recommendation, and places the evidentiary basis for the recommendation in the body — because its utility rests on clarity and actionability.

The Cochrane Collaboration, which produces the most rigorous systematic reviews in health research, has developed a series of plain language summaries and policy briefs specifically to bridge the gap between its reviews and policy audiences. The Cochrane Policy Liaison program, and the collaboration's work with the WHO to produce Evidence to Policy (EtP) briefs, represents an explicit acknowledgment that the systematic review alone does not accomplish the translation task.

Translating Absolute vs. Relative Risk for Non-Scientist Audiences

One of the most consequential translation decisions in health communication is the choice between absolute and relative risk framing. This choice affects how policymakers, journalists, and the public understand the magnitude of health risks and the effectiveness of interventions — and it is almost always made implicitly rather than deliberately by health researchers writing for general audiences.

A vaccine that reduces the risk of a disease from 0.2% to 0.1% has a relative risk reduction of 50% — which sounds like a major effect. It has an absolute risk reduction of 0.1 percentage points — which sounds like a minor effect. Both numbers are accurate. Research published in the British Medical Journal by Gigerenzer and colleagues has documented that physicians, patients, and policymakers systematically overestimate the clinical significance of interventions when they are described in relative rather than absolute terms.

For policy communication, the number that most directly relates to resource allocation decisions is the Number Needed to Treat (NNT) or Number Needed to Vaccinate (NNV) — the number of people who must receive the intervention for one person to benefit. An NNV of 1,000 for a vaccine against a low-incidence disease places the risk-benefit calculation in terms that a budget analyst can evaluate directly: how much does it cost to vaccinate 1,000 people, and how does that compare to the cost of treating one case of the disease?

The CDC's health communication research, including guidance from the CDC's Office of the Associate Director for Communication, specifically recommends presenting risk information in absolute terms with concrete denominators — "1 in 1,000 people who receive this vaccine will experience this side effect" rather than "the side effect rate is 0.1 percent" — because concrete denominators are more accurately processed by non-specialist audiences. This recommendation reflects a substantial evidence base in risk communication research.

Economic Framing in Health Policy Communication

Health research that influences policy most consistently includes an economic dimension. Cost-effectiveness analysis — which compares the cost per quality-adjusted life year (QALY) gained across different interventions — is the standard framework used by health economists and increasingly required by health technology assessment bodies like the UK's National Institute for Health and Care Excellence (NICE). A cost-effectiveness threshold of $100,000-$150,000 per QALY is commonly applied in US health policy contexts, though this threshold is not formally established in US federal policy as it is in the UK.

Burden of disease framing — the economic cost of a condition in terms of direct healthcare costs, productivity losses, and caregiver burden — is a complementary economic frame that presents the case for intervention in terms of costs that are already being incurred rather than costs of the proposed intervention. A policy brief on opioid addiction treatment that begins by quantifying the $78.5 billion annual cost of opioid misuse to the US economy (a figure from the CDC's National Center for Injury Prevention and Control, based on 2013 data and updated in subsequent analyses) is making the case for treatment investment in the terms a budget analyst uses.

The Robert Wood Johnson Foundation's guide to health policy communication identifies economic framing as the most effective single intervention for moving health research to policy attention. Research that cannot be stated in economic terms — that can demonstrate health benefits but cannot connect them to cost savings, productivity gains, or reduced demand on public resources — faces a harder path to policy influence regardless of its scientific quality.

How Health Communication Differs from Health Marketing

Health marketing — the use of communication strategies to change health behavior among target populations — is a distinct discipline from health policy communication, and conflating the two produces documents that serve neither purpose. Health marketing is designed to change individual behavior through persuasion. Health policy communication is designed to change institutional decisions through evidence.

The practical differences are significant. Health marketing emphasizes emotional resonance, personal relevance, and simplicity — the same message communicated across multiple channels at high frequency. Health policy communication requires technical precision, comprehensive coverage of counterarguments, and source credibility — the characteristics that make a document useful to a policy analyst who must defend their position to skeptical colleagues.

A document that frames the case for childhood vaccination in terms of personal family protection — effective health marketing for parents — does not provide what a state health officer needs to argue for mandatory vaccination in the legislature. The state health officer needs data on outbreak dynamics, herd immunity thresholds, historical outbreak costs, and legal precedents for mandatory vaccination programs. The emotional frame that moves parents does not move legislators, who have professional incentives to resist emotionally-framed arguments and respond to technically-grounded ones.

Examples of Health Research That Influenced Policy

The characteristics of health research that has successfully influenced major policy decisions are consistent and instructive for writers working in the field.

The Institute of Medicine's 1999 report To Err Is Human: Building a Safer Health System — which estimated that medical errors kill between 44,000 and 98,000 Americans annually — produced more immediate legislative and regulatory attention to patient safety than decades of prior research on the same topic. The communication difference was twofold: it translated academic research into a mortality estimate that journalists could report and policymakers could not ignore, and it translated the evidence base into specific actionable recommendations for each level of the healthcare system rather than a general call for quality improvement.

The Community Preventive Services Task Force, which produces systematic reviews and policy recommendations for community-level health interventions, uses a structured format that explicitly separates the evidence quality from the policy recommendation — and that explicitly includes economic evidence alongside health evidence in its recommendations. Its recommendations carry weight in state and local health department decisions in part because the format of its outputs matches the format health departments need for program justification to their funders.

These examples share a characteristic that applies broadly: effective health policy communication is not communication that happens to be accurate. It is communication that is deliberately designed to serve the decision the intended audience must make, in the format that audience uses, with the evidence framing that audience finds most compelling. That design is a writing task, not a research task — and it requires as much deliberate attention as the research it communicates.